Novartis is buying UK biotech Myricx Bio for $1.1 billion upfront, according to Endpoints News, which reported the deal was announced Monday. The Swiss drugmaker is acquiring Myricx's next-generation antibody-drug conjugate (ADC) platform, technology that Endpoints says could offer an edge over current approaches.
ADCs are a fast-growing class of cancer treatment. The idea is to attach a toxic "payload" to an antibody that homes in on tumor cells, delivering the poison directly to cancer while sparing healthy tissue. The key differentiator between rival ADCs is often the payload itself.
According to Endpoints News, Novartis will get Myricx's NMT payload platform as part of the transaction. PharmaTimes, citing a report from investor Sofinnova, framed the deal as pairing Novartis's oncology capabilities with Myricx Bio's next-generation ADC technology.
The reported figure of $1.1 billion is an upfront payment, a structure common in biotech acquisitions where additional milestone payments can follow if the technology hits development or sales targets. The sources here describe the upfront sum; they do not detail any further terms.
Why it matters: large pharmaceutical companies are competing aggressively to lock up novel ADC technology, and Novartis's willingness to commit more than a billion dollars upfront signals how central this class of targeted cancer drugs has become to the industry's future pipeline.